Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.440
-0.070 (-2.79%)
At close: Aug 1, 2025, 4:00 PM
2.450
+0.010 (0.41%)
After-hours: Aug 1, 2025, 7:48 PM EDT
Editas Medicine Revenue
Editas Medicine had revenue of $4.66M in the quarter ending March 31, 2025, with 310.40% growth. This brings the company's revenue in the last twelve months to $35.84M, down -48.37% year-over-year. In the year 2024, Editas Medicine had annual revenue of $32.31M, down -58.64%.
Revenue (ttm)
$35.84M
Revenue Growth
-48.37%
P/S Ratio
5.63
Revenue / Employee
$145,679
Employees
246
Market Cap
204.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
EDIT News
- 7 weeks ago - Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - GlobeNewsWire
- 2 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 2 months ago - Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - GlobeNewsWire
- 2 months ago - Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 2 months ago - Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 2 months ago - Editas Medicine Announces First Quarter 2025 Results and Business Updates - GlobeNewsWire
- 2 months ago - Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board - GlobeNewsWire